Lei Zhang

Position:

VP, Research

Education Background:

Ph.D. in Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and Postdoctoral Fellow, Friedrich Miescher Institute for Biomedical Research, Switzerland

Profile:

Dr. Lei Zhang has been working on molecular biology of inflammatory response, tumor neovascularization and tumor formation, and is dedicated to the R&D of cell therapies. He worked at Fosun Kite Biotechnology, where he was responsible for technology transfer of Yescarta from Kite Pharma, which was approved by the NMPA as first CAR-T product in China. He also led early development of several internal innovative CAR-T research programs for solid tumor therapy, leading to 6 patent applications. Dr. Zhang has published several papers in Nature Immunology, Cancer Research, Current Biology, among others.